
Ceritinib demonstrates efficacy in brain metastases in ALK+ NSCLC
Results from ASCEND-7 trial confirms the place of ceritinib as a standard treatment option for patients with ALK+ non-small-cell lung cancer and active brain metastases

Over one hundred ESMO research fellows in 30 years
2019 marks the 30th Anniversary of the ESMO Fellowship Programme, a programme that has provided many young oncologists valuable educational opportunities, shaped professional lives and enhanced careers